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Abstract
Background: Cochrane systematic reviews collate and summarise studies of the effects of healthcare interventions.
The characteristics of these reviews and the meta-analyses and individual studies they contain provide insights into
the nature of healthcare research and important context for the development of relevant statistical and other
methods.
Methods: We classified every meta-analysis with at least two studies in every review in the January 2008 issue of
the Cochrane Database of Systematic Reviews (CDSR) according to the medical specialty, the types of interventions
being compared and the type of outcome. We provide descriptive statistics for numbers of meta-analyses,
numbers of component studies and sample sizes of component studies, broken down by these categories.
Results: We included 2321 reviews containing 22,453 meta-analyses, which themselves consist of data from
112,600 individual studies (which may appear in more than one meta-analysis). Meta-analyses in the areas of
gynaecology, pregnancy and childbirth (21%), mental health (13%) and respiratory diseases (13%) are well
represented in the CDSR. Most meta-analyses address drugs, either with a control or placebo group (37%) or in a
comparison with another drug (25%). The median number of meta-analyses per review is six (inter-quartile range 3
to 12). The median number of studies included in the meta-analyses with at least two studies is three (inter-
quartile range 2 to 6). Sample sizes of individual studies range from 2 to 1,242,071, with a median of 91
participants.
Discussion: It is clear that the numbers of studies eligible for meta-analyses are typically very small for all medical
areas, outcomes and interventions covered by Cochrane reviews. This highlights the particular importance of
suitable methods for the meta-analysis of small data sets. There was little variation in number of studies per meta-
analysis across medical areas, across outcome data types or across types of interventions being compared.
Background
Systematic reviews of randomized trials provide valuable
evidence on the effectiveness of healthcare interventions,
maximising power, minimising bias and avoiding undue
emphasis on the results of individual studies. Many sys-
tematic reviews contain meta-analyses, in which the
results from independent studies are formally combined
using statistical methods. The Cochrane Database of
Systematic Reviews (CDSR) is a major resource of sys-
tematic reviews on the effects of healthcare interven-
tions that are periodically updated [1,2]. The reviews in
the CDSR are prepared by members of The Cochrane
Collaboration, which aims to make the findings from
systematic reviews of interventions conveniently avail-
able so that healthcare consumers, professionals and
providers can make choices about healthcare interven-
tions using the most up-to-date and reliable evidence
available on their relative effects [3]. The initiative is
worldwide in its scope, involving input from more than
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27,000 contributors in over 100 different countries, who
work with the Cochrane Review Groups responsible for
reviews in particular areas of health and health care [4].
As of 2011, more than 4,500 full Cochrane reviews have
been produced and published protocols are available for
nearly 2,000 more reviews that are at earlier stages in
their development.
The objective of this paper is to report descriptive sta-
tistics relating to one complete issue of the CDSR, pub-
lished in January 2008. We have classified each meta-
analysis in the CDSR by types of interventions, type of
outcome and medical specialty. In further work, the
classifications will allow us to examine empirically the
magnitude and variation of among-study heterogeneity
in meta-analyses, enabling us to understand how certain
characteristics influence the level of between-study het-
erogeneity. In this paper, we have described our meth-
ods for collating this collection of more than 22,000
meta-analyses and reported statistics relating to the
interventions, outcomes and medical areas investigated
in these meta-analyses. We have summarised the sizes
of reviews, meta-analyses and studies in the CDSR, and
explored how these vary across different settings.
A number of earlier papers have analysed large collec-
tions of systematic reviews and meta-analyses for other
purposes. For example, Moher et al. [5] examined a
cross-sectional sample of 300 systematic reviews
(Cochrane and non-Cochrane) published in one month,
and focused on their quality and reporting characteris-
tics. A series of meta-epidemiological studies have ana-
lysed collections of meta-analyses in order to estimate
the association between methodological flaws such as
inadequate allocation concealment or inadequate blind-
ing in randomised trials and exaggeration of the inter-
vention effect; data from several of these studies were
recently combined by Wood et al. [6]. Bow et al. [7]
have described the characteristics of all Cochrane
reviews relevant to child health, 1046 in total. To our
knowledge, the characteristics of the entire Cochrane
database have not previously been summarised, and the
types of interventions and outcomes to which the meta-
analyses within Cochrane reviews relate have not been
examined in detail.
Methods
The full content of the first issue from 2008 of the CDSR
was provided to us by the Nordic Cochrane Centre. The
highly structured nature of every Cochrane review
allowed us to focus on the sections of each review cover-
ing ‘Data and analyses’, and on any pair-wise compari-
sons of interventions reported and the outcomes within
these. Each outcome could contain several subgroups of
studies, and each subgroup could contain data from sev-
eral studies. This structure is illustrated in Figure 1.
Eligibility criteria
We were interested in all full reviews of the effects of
health or social care interventions published in Issue 1,
2008 of the CDSR that reported at least one eligible
meta-analysis (see below). We excluded protocols for
reviews, reviews from the Cochrane Methodology
Review Group, and reviews that had been marked as
withdrawn.
We defined an eligible meta-analysis as a forest plot
that had been generated using the Review Manager
(RevMan) software [8], and that included data from at
least two different studies. We discarded forest plots
with a single study, since a meta-analysis would not be
performed on a single study, and because Cochrane
review authors are often discouraged from including for-
est plots when there is only one study, meaning that any
such forest plots published in Cochrane reviews would
not be a representative sample. We included forest plots
irrespective of whether review authors had elected to
display the results of the meta-analysis within them. In
some forest plots, the subgroups presented within an
outcome were not mutually exclusive, since the same
study data may be included in more than one subgroup.
We therefore checked as far as possible for study dupli-
cations and extracted data for only the first occurrence
of each study in each forest plot.
The CDSR includes four types of data which systema-
tic review authors have extracted from the included stu-
dies: binary data, continuous data, generic results and
“O-E and variance” data. Binary data and continuous
data have been entered directly into RevMan as num-
bers of events or means and standard deviations,
together with numbers of participants in each
Figure 1 Illustration of the hierarchy of a ‘Data and analyses’
section of a Cochrane review. Reproduced with permission from
Chapter 4 of the Cochrane Handbook for Systematic Reviews of
Interventions.
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intervention group in each study. Generic results have
been entered as an effect estimate with corresponding
standard error for each study, and “O-E and variance”
data have been entered as the observed-minus-expected
number of events and variance for each study. Generic
results include time-to-event outcomes (e.g. analysed as
hazard ratios) and ordinal outcomes (e.g. analysed as
odds ratios), as well as binary or continuous data from
studies with complex designs, while “O-E and variance”
data are typically derived from time-to-event outcomes.
We analysed these latter two data types together as
mixed outcome data.
There were occasional mistakes in how the review data
had been entered into the hierarchy of the database, one
common example being subgroups listed as if they were
separate outcomes. A handful of reviews did not provide
the names of the outcome measures to which their
reported meta-analyses related. Incorrectly entered
review information (be it at the level of individual meta-
analyses or whole reviews) was corrected manually wher-
ever possible, or excluded if the appropriate form of the
data was impossible to determine. Furthermore, we
excluded data from the large number of studies in the
database that appeared to have a sample size of 2, with 0/
1 events recorded in each group for studies with binary
outcomes, means and standard deviations of 0 in each
group for studies with continuous outcomes, or O-E and
variance of 0 for studies with “O-E and variance” data.
These data patterns arose because of the way that forest
plots in the version of RevMan used up to 2008 stored
information on studies that were listed in the plot but
without contributing data to the specific meta-analysis,
and it is likely that almost all of these studies do not
represent genuine data. Studies of sample size 2 with a
different data pattern recorded were not excluded. The
flow diagram in Figure 2 illustrates where and why meta-
analyses or studies were excluded.
Classification schemes
Each eligible meta-analysis within each review was clas-
sified by medical specialty, types of interventions
involved in the pair-wise comparison and type of out-
come. To classify medical specialties, we used 11 cate-
gories from a taxonomy [9] developed by the UK
National Institute for Health and Clinical Excellence
(NICE) (see Table 1). Our classification scheme for
interventions was based on the Health Research Classifi-
cation System [10] developed by the UK Clinical
Research Collaboration (UKCRC). Our outcome cate-
gories were based on those used by Wood [11], and the
Foundation for Health Services Research [12]. During a
pilot study (see below), some amendments to our initial
schemes were made. Our final classifications contained
17 categories for type of intervention (15 ‘active’ and
two ‘control’) and 23 categories for type of outcome
(Tables 2 and 3). Two general outcome categories were
included: “infection/onset of new acute/chronic disease”
and “symptoms/signs reflecting continuation or end of
condition”. These categories cover the many outcomes
with loose descriptions such as “absence of disease” or
“no improvement” where the method of outcome mea-
surement is unclear.
Pilot study
A pilot study was built into our research. We sampled
one Cochrane review from each of the 49 Cochrane
Review Groups (excluding the Cochrane Methodology
Review Group) from Issue 4, 2007 of the CDSR. The
meta-analyses in these reviews were independently classi-
fied for outcomes and interventions by three people (JD,
RMT and JPTH). Disagreements were discussed and
used to refine the lists of categories for the main study.
Data collection and management
The CDSR data for Issue 1, 2008 were imported into
Microsoft® Office Access. To facilitate classifications,
relevant summary information for each systematic
review were extracted into a Microsoft Access form,
drawing on various hard-coded elements of a Cochrane
review [Box 2.2.b in Cochrane Handbook [3]]. In parti-
cular, the form provided rapid access to (i) the review’s
title; (ii) short text descriptions of interventions and out-
comes from the captions of each forest plot; (iii) detailed
review eligibility criteria for participants, interventions
and outcomes; (iv) objectives, selection criteria and
results from the review’s abstract; and (v) descriptions of
participants, interventions and outcomes for up to five
studies with the highest statistical weight in the first
meta-analysis of the review. Reviews with no meta-ana-
lyses, and forest plots with fewer than two studies were
not extracted into the Access forms.
Classifications were performed directly into the Access
form by a single person (JD), who consulted other
authors (JPTH, RMT) when uncertain of the most
appropriate choice. In practice, classifications of inter-
ventions and outcomes were based primarily on review
titles and short text captions from forest plots. The out-
come categories were ordered so that outcomes poten-
tially falling under multiple categories would be
classified as the category highest on the list. Classifica-
tion of medical specialties was performed by a single
person (MJC), and was usually based on the review title,
with the abstract consulted if necessary.
Statistical analysis
We present tabular descriptive statistics for various
characteristics of the eligible meta-analyses in CDSR.
We summarise how the database is comprised with
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regards to pair-wise intervention categories, outcome
categories and medical specialty areas. We present
descriptive results pertaining to the reviews (number of
meta-analyses and number of comparisons per review),
comparisons (number of outcomes per comparison),
meta-analyses (number of studies per meta-analysis) and
studies (sample size of individual studies). We also
describe the relationships between these characteristics
and the different category groupings used for interven-
tions, outcomes and medical specialties.
Results
Of a total of 5171 records in the CDSR (Issue 1, 2008),
3385 were reviews rather than protocols, and 2492 of
Meta-analyses assessed for eligibility 
(62510 MAs including 254306 
studies)
Excluded from classifications: MA labelled 
as subgroup analysis or sensitivity analysis; 
or insufficient information for classification 
(10837 MAs including 84501 studies) 
Numeric data excluded 
i Studies included multiple times in one 
MA, repeats excluded (27434 studies) 
i Single-study MAs (29205 MAs) 
i Studies suspected of having erroneous 
data (15 MAs comprised entirely of 66 
such studies, 500 additional studies) 
1
Mixed outcome MAs 
(895 MAs including 
5461 studies) 
Continuous outcome MAs 
(6672 MAs including 
29902 studies) 
Binary outcome MAs 
(14886 MAs including 
77237 studies) 
Classified meta-analyses analysed 
(22453 MAs including 112600 studies) 
Figure 2 Flow diagram showing eligibility and exclusions of meta-analyses and studies.
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these met our eligibility criteria and contained at least
one eligible meta-analysis of two or more studies. Fol-
lowing the removal of ineligible meta-analyses (Figure
2), we were left with 2321 reviews, which contained
22,453 meta-analyses. These meta-analyses incorporate
data from 112,600 studies.
Types of medical specialty
The medical specialties of the 22,453 meta-analyses are
given in Table 1. The category “Gynaecology, pregnancy
and birth” is the most frequently occurring, accounting
for over a fifth (21%) of all meta-analyses. This reflects
the fact that the Pregnancy and Childbirth Group and
the Neonatal Group are two of the four Cochrane
Review Groups which have produced the highest num-
bers of reviews. The two next largest categories are
“Respiratory diseases” (13%) and “Mental health and
behavioural conditions” (13%). The variation across
medical areas partly reflects differences in longevity
among the Cochrane Review Groups, as well as differ-
ences in research activity.
Types of interventions
Each meta-analysis makes a comparison of two interven-
tions, and each of the interventions was categorised
separately, with the initial intervention in the pair being
considered the “active” intervention and the second
intervention being the “comparator”. The distribution of
the comparisons made in the 22,453 meta-analyses is
summarised in Table 2. As one might expect in a data-
base of reviews of the effects of health care, the CDSR is
dominated by pharmacological interventions. The initial
intervention listed is pharmacological in just under two-
thirds (63%) of all pair-wise interventions examined. In
addition to its primary importance as an active interven-
tion, the pharmacological category also comprises over a
quarter (26%) of all comparator interventions in the
CDSR. The most common pair-wise comparison is of a
Table 1 Distribution of medical specialties for the 22453
eligible meta-analyses in our sample
Medical Specialty Frequency
Cancer 905 (4%)
Cardiovascular 1693 (8%)
Central nervous system/musculoskeletal 1965 (9%)
Digestive/endocrine, nutritional and metabolic 2704 (12%)
Gynaecology, pregnancy and birth 4656 (21%)
Infectious diseases 965 (4%)
Mental health and behavioural conditions 2918 (13%)
Pathological conditions, symptoms and signs 701 (3%)
Respiratory diseases 3021 (13%)
Urogenital 1289 (6%)
Other1 1637 (7%)
Total 22453
1 Other: Blood and immune system, Ear and nose, Eye, General health,
Genetic disorders, Injuries, accidents and wounds, Mouth and dental, Skin
Table 2 Distribution of Pair-wise Interventions in meta-analyses in the CDSR
Second Intervention
First Intervention vs.
Control
vs.
Placebo
vs.
Pharm
Vs. Non-Pharm1 from same
category
vs. Non-Pharm1 from different
category
Total
Pharmacological 4027
(18%)
4321
(19%)
5571
(25%)
n/a 186 (<1%) 14105
(63%)
Vaccines 95 (<1%) 113 (<1%) 0 (0%) 49 (<1%) 0 (0%) 257 (1%)
Surgical 241 (1%) 2 (<1%) 29 (<1%) 1204 (5%) 86 (<1%) 1562 (7%)
Medical devices 706 (3%) 50 (<1%) 82 (<1%) 941 (4%) 159 (<1%) 1938 (9%)
Cellular and gene 29 (<1%) 6 (<1%) 0 (0%) 57 (<1%) 7 (<1%) 99 (<1%)
Radiotherapy 124 (<1%) 65 (<1%) 3 (<1%) 56 (<1%) 63 (<1%) 311 (1%)
Physical 318 (1%) 10 (<1%) 8 (<1%) 72 (<1%) 39 (<1%) 447 (2%)
Educational 303 (1%) 4 (<1%) 1 (<1%) 34 (<1%) 27 (<1%) 369 (2%)
Behavioural 380 (2%) 7 (<1%) 3 (<1%) 165 (<1%) 14 (<1%) 569 (3%)
Screening 17 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 17 (<1%)
Complementary 216 (1%) 104 (<1%) 41 (<1%) 8 (<1%) 19 (<1%) 388 (2%)
Psychological 379 (2%) 1 (<1%) 6 (<1%) 116 (<1%) 44 (<1%) 546 (2%)
Resources and
infrastructure
506 (2%) 0 (0%) 14 (<1%) 52 (<1%) 33 (<1%) 605 (3%)
Complex 505 (2%) 36 (<1%) 43 (<1%) 200 (<1%) 154 (<1%) 938 (4%)
Other 188 (1%) 44 (<1%) 8 (<1%) 51 (<1%) 11 (<1%) 302 (1%)
Total 8034
(36%)
4763
(21%)
5809
(26%)
3005 (13%) 842 (4%) 22453
1Non-Pharm = all intervention categories as listed for the First intervention, other than Pharmacological
n/a = not applicable
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pharmacological versus a pharmacological intervention
(25%), followed by pharmacological versus placebo
(19%) and pharmacological versus control (18%). These
three pair-wise interventions account for over 60% of all
comparisons in the CDSR. The distinction between pla-
cebo and control might not be an accurate representa-
tion, since review authors may have coded placebo as
‘control’ when specifying their interventions. Combining
the placebo and control comparators suggests that 37%
of meta-analyses evaluated the fundamental efficacy of a
pharmacological intervention.
Overall, the most common comparator intervention is
control (which we defined as a control intervention
which is not explicitly labelled or described as placebo;
examples include “usual care” and “no treatment”). Con-
trol groups are present in over one third (36%) of all
pair-wise comparisons. Placebos account for over one
fifth (21%) of comparators and are predominantly paired
with active pharmacological interventions: 4321/4763
(91%) of all placebo-controlled comparisons relate to
pharmacological rather than non-pharmacological
interventions.
Comparisons of a non-pharmacological intervention
with an intervention from the same category are
reasonably common in the CDSR (13%). These are prin-
cipally comparisons between surgical procedures (5%) or
medical devices (4%). Surgical procedures in particular
are frequently compared with another from the same
intervention category; 1204 of the 1562 surgical meta-
analyses (77%) compared two surgical procedures. Medi-
cal devices (9%) and surgery (7%) are the two most fre-
quently occurring initial intervention types after
pharmacological interventions.
Types of outcome
Table 3 presents the types of outcomes assessed in the
22,453 meta-analyses. The largest outcome category is
signs or symptoms reflecting the continuation or end
of a medical condition (16%). This is a broad category,
which includes commonly recorded outcomes such as
“presence/absence of disease” (in a non-preventative
review) and “clinical improvement”. These types of
outcome are routinely measured in a large number of
healthcare areas. Following this in order of size is the
category of adverse events (11%). Many outcomes
included in this category were simply labelled “adverse
events”, while some had a more specific label such as
“adverse events: weight gain”, and other outcomes such
as “headache” were assigned to this category if the
review title and objectives suggested they related to
side effects rather than the main effect of the interven-
tion. Another large category is infection or onset of a
new acute or chronic disease (10%), which is largely
comprised of binary outcomes from reviews which
investigated whether treatments aimed at prevention of
a particular illness had succeeded or failed.
Biological markers (9%) include quantifiable biologi-
cal parameters, typically measured in a laboratory,
such as blood components (e.g. CD4 count). General
physical health measures (9%) include all physical
health measurements manually assessed by the clini-
cian. This includes routine measures such as heart rate
or BMI. Obstetric outcomes (7%) are heavily repre-
sented by the two afore-mentioned, large Cochrane
Review Groups covering pregnancy, childbirth and
neonatal care. This category includes binary events
such as becoming pregnant or having a miscarriage, as
well as continuous outcomes such as fetal measure-
ments or information on gestational age. The most
objectively defined category is all-cause mortality,
which comprises 6% of the outcomes. These outcomes
were usually labelled as “All-cause mortality”, but we
also assigned phrases such as “Survival” and “Neo-natal
mortality” to this category.
The seven categories discussed above represent two-
thirds of all the outcomes in the CDSR, with the
remaining third split between the other 16 outcome
categories (Table 3).
Table 3 Distribution of Outcomes in meta-analyses in the
CDSR
Outcome Frequency
Signs/symptoms reflecting continuation/end of
condition
3639 (16%)
Adverse events 2368 (11%)
Infection/onset of new acute/chronic disease 2215 (10%)
Biological markers (e.g. VO2 max) 2071 (9%)
General physical health (e.g. heart rate) 1921 (9%)
Obstetric outcomes 1477 (7%)
All-cause mortality 1278 (6%)
Hospital stay/process measures 1158 (5%)
Quality of life/functioning 958 (4%)
Pain 802 (4%)
Mental health outcomes 743 (3%)
Surgical/device related success/failure 737 (3%)
Withdrawals/dropouts 643 (3%)
Internal structure (e.g. radiograph outcomes) 504 (2%)
Major morbidity event (e.g. stroke) 502 (2%)
Composite (at least 1 non-mortality/morbidity) 460 (2%)
Composite (mortality/morbidity only) 224 (1%)
Cause-specific mortality 194 (1%)
Consumption (e.g. use of beta2 agonists) 190 (1%)
External structure (e.g. eczema) 160 (1%)
Other 94 (0.4%)
Satisfaction with care 86 (0.4%)
Resource use 29 (0.1%)
Total 22453
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Composition of systematic reviews
The majority (61%) of the 2321 reviews that contained
at least one eligible meta-analysis included only one
pair-wise comparison of interventions (Table 4). 86% of
reviews measured outcomes for three or fewer compari-
sons and only 4% looked at seven or more. On closer
examination of a review which appeared to report meta-
analyses for the largest number of comparisons, some of
the 23 comparisons were found to relate to different
methods of combining data rather than separate pair-
wise comparisons of interventions. The largest number
of genuinely different pair-wise comparisons was 20, in
a review comparing the effectiveness of interventions for
preventing hypotension in women having Caesarean sec-
tion under spinal anaesthesia [13].
The median number of outcomes per comparison was
three (inter-quartile range 1 to 6; Table 4). In 25% of all
4755 comparisons, only one outcome was reported. Sev-
eral reviews included large numbers of outcomes relat-
ing to the same comparison, with 17% of all reviews
including at least one comparison that looked at more
than ten outcomes.
Of the 2321 reviews in the data set (which all included
at least one meta-analysis of two or more studies), just
under 10% contained only one meta-analysis. At the
other end of the spectrum, one in ten reviews contained
22 or more meta-analyses. We note again that forest
plots reporting results for two or more studies were
regarded as meta-analyses, irrespective of whether
review authors had elected to display the meta-analysis
results. The median number of meta-analyses included
in a review was six (inter-quartile range 3 to 12). The
distribution exhibits positive skew, with five reviews
examining more than 100 meta-analyses, the maximum
being 128, in a review comparing immunosuppressive
regimens for treating kidney transplant recipients [14].
Number of studies per meta-analysis
In our sample of 22,453 meta-analyses from the CDSR,
which needed to contain at least two studies to be eligi-
ble, the median number of included studies was three
(inter-quartile range 2 to 6; see Table 5). Over a third
(36%) of the meta-analyses included the minimum
requirement of two studies only, and just under three
quarters (75%) contained five or fewer studies.
Some of the more widely studied medical specialty
areas in the CDSR include meta-analyses that are able
to draw upon a wealth of studies, the largest containing
294 [15], whilst 1% of meta-analyses contain 28 studies
or more. Among the 11 specialty categories we used,
cancer had a slightly higher median number of included
studies (5) than any of the other categories.
There is no clear evidence to suggest that the number
of studies per meta-analysis is strongly related to the
outcome data type, or to the types of interventions
being compared. Meta-analyses of all-cause mortality
appear to contain slightly larger numbers of studies than
other types of outcome. A Wilcoxon rank-sum test
comparing the numbers of studies in meta-analyses of
all-cause mortality vs. all other outcome types gave a P-
value of 0.001; however, this analysis was not pre-speci-
fied and should be interpreted with caution.
Study sample size
Sample size of individual studies varies considerably
across reviews and meta-analyses in the CDSR (Table 6):
from very small studies containing only two individuals,
up to some very large studies aiming to investigate the
efficacy of vaccines or the impact of screening, which
contained hundreds of thousands or even millions of
individuals. The overall mean sample size for studies in
the CDSR is 513. However, the distribution of sample
sizes is better summarised by the median of 91 and the
inter-quartile range of 44 to 210.
Studies reporting dichotomous data have a median
size of 102 and an inter-quartile range of 50 to 243,
whereas studies reporting continuous data have a
lower median size (62) and inter-quartile range (33 to
142). This may be because continuous outcomes (e.g.
blood pressure or change in peak expiratory flow) tend
to be more complex and labour-intensive to measure,
making them unsuitable as outcomes in very large stu-
dies. On the other hand, dichotomous outcomes such
as presence or absence of disease can be collected in a
quick and more efficient manner for large numbers of
individuals. In addition, statistical power tends to be
higher for continuous outcomes than for dichotomous
outcomes, so sample size calculations will generally
lead to lower sample sizes when the primary outcome
is continuous.
Study sizes show notable variation across medical spe-
cialties. The medians and quartiles are highest in cancer,
and high also for meta-analyses in the areas of infectious
diseases and gynaecology, pregnancy and birth. Study
sizes tend to be lower in the areas of mental health and
behavioural conditions and pathological conditions,
symptoms and signs.
Table 4 Number of comparisons per review, outcomes
per comparison and meta-analyses per review in the
CDSR.
Min 25% Median 75% Max
Number of comparisons in 2321
reviews
1 1 1 2 23
Number of outcomes in 4755
comparisons
1 1 3 6 68
Number of meta-analyses in 2321
reviews
1 3 6 12 128
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There is relatively little variation in medians and inter-
quartile ranges of sample size across different types of
intervention comparison. However, the maximum sam-
ple size for pair-wise interventions comparing non-phar-
macological interventions against control or placebo is
substantially larger than for the other categories. This
can be explained by the fact that the largest studies
such as those involving vaccines or screening are
included under this category.
Across outcome types, sample sizes are highest for the
category including cause-specific mortality, major
morbidity events and composite mortality/morbidity
events, and are lowest for biological markers and general
physical health measures.
Discussion
The CDSR provides high quality evidence on the effects
of healthcare interventions and is widely cited in all
areas of medicine. To our knowledge, we report the lar-
gest study which has classified and described the charac-
teristics of the entire collection of meta-analyses
contained within the CDSR, although many previous
Table 5 Number of studies per meta-analysis, overall and broken down by outcome type, intervention comparison
type and medical area
Meta-
analyses
50%
1
75% 90% 99% Max
All Total 22453 3 6 10 28 294
Data type Dichotomous 14886 3 6 10 28 294
Continuous 6672 3 5 8 24 98
Mixed 895 4 7 12 46 133
Medical
specialty
Cancer 905 5 8 14 43 69
Cardiovascular 1693 4 7 13 38 58
Central nervous system/musculoskeletal 1965 3 5 8 21 49
Digestive/endocr., nutritional and metabolic 2704 4 6 11 31 138
Gynaecology, pregnancy and birth 4656 3 5 8 20 76
Infectious diseases 965 3 5 9 27 63
Mental health and behavioural conditions 2918 3 5 10 30 174
Pathological conditions, symptoms and signs 701 3 6 10 31 294
Respiratory diseases 3021 3 5 8 20 39
Urogenital 1289 3 5 9 21 31
Other 1636 3 6 10 34 133
Interventions Pharm. vs. Control/Placebo 8348 3 6 10 30 294
Pharm. vs. Pharm. 5571 3 6 10 28 174
Pharm. vs. Non-Pharm. 424 3 5 11 25 36
Non-Pharm. vs. Control/Placebo 4449 3 5 9 25 61
Non-Pharm. vs. Non-Pharm. 3661 3 5 9 28 58
Outcomes Signs/symptoms reflecting continuation/end of condition 3639 3 5 9 29 110
Adverse events 2368 3 6 10 26 270
Infection/onset of new acute/chronic disease 2215 3 6 10 24 294
Biological markers 2071 3 6 10 28 138
General physical health 1921 3 5 9 27 58
Obstetric outcomes 1477 3 6 11 24 76
All-cause mortality 1278 4 8 13 36 75
Resource use/hospital stay/process 1187 3 5 9 27 99
Cause-specific mortality/major morbidity event/composite (mortality or
morbidity)
920 4 6 11 34 133
Other outcomes (semi-objective)2 2044 3 6 11 30 174
Other outcomes (subjective)3 3239 3 5 9 23 69
1Minimum values and 25th percentiles are not listed, since these were identical across most meta-analysis types. The minimum value was 2 in all rows (noting
that meta-analyses needed to contain at least 2 studies to be eligible for inclusion). The 25th percentile was 3 for Cancer and All-cause mortality, and 2 in every
other row.
2Other outcomes (semi-objective): External structure, Internal structure, Surgical/device related success/failure, Withdrawals/drop-outs
3Other outcomes (subjective): Pain, Mental health outcomes, Quality of life/functioning, Consumption, Satisfaction with care, Composite (at least 1 non-mortality/
morbidity)
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studies have explored characteristics of subsets of the
CDSR. Our descriptive analysis provides information on
the frequencies of different outcome types, intervention
types and medical specialties in the CDSR, and sum-
marizes the distributions of meta-analysis and study
size, overall and within different settings.
Our results show that the majority of meta-analyses in
the CDSR evaluate pharmacological interventions, either
in comparison with placebo or control (37%) or in com-
parison with another pharmacological intervention
(25%). The most frequently examined non-pharmacolo-
gical interventions were medical devices (9%) and surgi-
cal procedures (7%). The number of studies per meta-
analysis was typically very small, with an overall median
of 3 (inter-quartile range 2 to 6). When a meta-analysis
includes very few studies, it is difficult to estimate the
between-study variance, and researchers may choose to
summarize the results narratively only. Meta-analyses
containing 5 or fewer studies are generally viewed as
small meta-analyses, in which statistical synthesis may
be problematic [16,17], and almost 75% of meta-analyses
in the CDSR fall into this category. However, our ana-
lyses include all data presented in forest plots, even
where the review authors had chosen not to display the
result of the meta-analysis, and numbers of studies are
likely to be lower in these cases than in meta-analyses
where the result was displayed.
The distribution of number of studies per meta-analy-
sis was consistent across many of the different outcome
types, intervention comparison types and medical
Table 6 Study sample size, overall and broken down by outcome type, intervention comparison type and medical
area
Studies 25% 50% 75% Max
All Total 112600 44 91 210 1242071
Data type Dichotomous 77237 50 102 243 1242071
Continuous 29902 33 62 142 18851
Mixed 5461 21 86 251 36511
Medical specialty Cancer 6441 72 154 326 266064
Cardiovascular 10686 44 102 289 67800
Central nervous system/musculoskeletal 8299 43 80 149 9440
Digestive/endocr., nutritional and metabolic 15345 42 79 160 18819
Gynaecology, pregnancy and birth 20098 60 118 293 23697
Infectious diseases 4502 59 130 371 419748
Mental health and behavioural conditions 15218 36 63 165 9020
Pathological conditions, symptoms and signs 4448 40 61 115 2463
Respiratory diseases 13153 36 87 227 82892
Urogenital 5914 39 71 153 4912
Other 8496 44 90 198 1242071
Interventions Pharm. vs. Control/Placebo 44156 41 90 222 58050
Pharm. vs. Pharm. 28018 48 99 222 25180
Pharm. vs. Non-Pharm. 2018 50 74 135 7711
Non-Pharm. vs. Control/Placebo 20892 41 92 229 1242071
Non-Pharm. vs. Non-Pharm. 17516 45 85 169 82892
Outcomes Signs/symptoms reflecting continuation/end of condition 17621 42 83 197 359600
Adverse events 11898 49 100 242 82892
Infection/onset of new acute/chronic disease 11284 56 110 258 1242071
Biological markers 10578 35 64 147 266064
General physical health 8959 30 66 177 131271
Obstetric outcomes 7376 60 117 293 18453
All-cause mortality 8302 52 110 281 259627
Resource use/hospital stay/process 5454 50 98 200 419748
Cause-specific mortality/major morbidity event/composite (mortality or morbidity) 5413 69 165 449 266064
Other outcomes (semi-objective)1 10886 44 81 177 131271
Other outcomes (subjective)2 14490 38 71 162 359600
1Other outcomes (semi-objective): External structure, Internal structure, Surgical/device related success/failure, Withdrawals/drop-outs
2Other outcomes (subjective): Pain, Mental health outcomes, Quality of life/functioning, Consumption, Satisfaction with care, Composite (at least 1 non-mortality/
morbidity)
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specialties. Meta-analyses in cancer tended to include
slightly more studies compared with meta-analyses in
other medical areas, as did meta-analyses of all-cause
mortality compared with those investigating other out-
comes. There was much greater variation across the
categories in the distribution of the sample sizes of indi-
vidual studies. Sample sizes were lower for studies mea-
suring labour-intensive outcome types such as biological
outcomes and tended to be higher for studies of dichot-
omous outcomes such as mortality and morbidity
events. Sample sizes also varied substantially across
medical specialties.
One limitation of our study is that classifications of
meta-analysis characteristics were carried out by only
one assessor. Due to the very large scale of the study,
the classification work required several months for com-
pletion and it was not possible for two authors to
undertake this. However, cases in which the appropriate
categorisation was unclear were discussed with one of
the other authors, and steps were taken to ensure con-
sistency across the classifications. Extraction of the data
was automated, since manual extraction was not practi-
cal for such a large data set, so our analyses relied on
the information that had already been entered by the
review authors. Efforts were made to exclude duplica-
tions of the same study within a meta-analysis, where
the meta-analysis included subgroups which were not
mutually exclusive. Identification of duplicates was
based on the study identifier appearing twice in an iden-
tical form, and it is possible that some duplicates were
missed through being labelled slightly differently (for
example as “Smith 2001a” and “Smith 2001b”). Variation
in the labelling of studies across Cochrane reviews
meant that manual data extraction would be required to
obtain a unique identifier for each study; therefore we
were unable to examine overlap among different meta-
analyses. Within reviews, studies often contribute data
to multiple meta-analyses relating to different outcomes
and comparisons. Studies may also appear in multiple
reviews, either contributing identical data or contribut-
ing data for different outcomes and comparisons. The
descriptive analyses of study sample size (Table 6)
should therefore be interpreted with caution, since some
studies are over-represented in the data set.
This research offers an insight into the characteristics
of the meta-analyses which make up the CDSR. In other
areas of this research project we have used these data to
investigate the distribution of between-study heteroge-
neity across meta-analyses, and explore which meta-ana-
lysis characteristics influence the degree of heterogeneity
[18]. In later work, we plan to explore the factors which
influence the degree of inconsistency among studies
[19].
Conclusions
It is clear that the numbers of studies eligible for
meta-analyses are typically very small for all medical
areas, outcomes and interventions covered by
Cochrane reviews. This highlights the particular
importance of suitable methods for the meta-analysis
of small data sets. There was little variation in number
of studies per meta-analysis across medical areas,
across outcome data types or across types of interven-
tions being compared. Sample sizes of individual stu-
dies within meta-analyses varied considerably across
reviews and meta-analyses. Among medical specialties,
study sizes were found to be highest in meta-analyses
related to cancer, infectious diseases, or gynaecology,
pregnancy and birth, and lowest in the areas of mental
health and behavioural conditions and pathological
conditions, symptoms and signs.
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